SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU.X is trending as community members highlight the project's strong IRL presence, expanding brand, and dedicated community efforts. There is excitement around holder growth, new partnerships, and the upcoming Maestro competition, driving bullish sentiment. The community emphasizes the project's focus on building and real-world utility.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the meme-based token and its presence on the Solana blockchain. Many are asking, 'What's Updog?', driving engagement and curiosity, while others celebrate its continued presence and growth in the crypto space. Built on Solana, UpDog is aiming to be the next big meme coin.

PHUMPTOM (PHUM) is a meme token, the symbol of which is a phantom. The story of this character is built around trading, and according to legend, he was born on the pump platform.fun from the energy of green candles. Now it is a symbol of green charts, the keeper of green candles. His presence portends growth, and he brings good luck to traders.  A positive character who tells his story like an adventure, generates memes where he always rushes to the aid of traders and gives good luck to holders.

PHUMPTOM

PHUM.X is trending as community members signal strong buy opportunities, encouraging others to get in early. The coin is generating buzz with some users drawing comparisons to other Solana-based tokens while also congratulating it on trending with UpDog. Community sentiment suggests confidence in a potential breakout and future growth for PHUM.X.

BlackBerry Ltd

BlackBerry is trending as the community discusses the integration of QNX OS with NVIDIA's DRIVE AGX Thor platform and potential revenue growth from IOT. The focus is on QNX's role in automotive and robotics, along with speculation about upcoming earnings and partnerships. Community members highlight the company's shift towards software and secure communications.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending due to recent exchange listings and high trading volume, sparking excitement within the crypto community. Many compare it to other high-potential projects, and are discussing its backers while anticipating further price increases. The community is closely watching for continued momentum.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter ($JUP.X) is trending due to discussions around its ecosystem, including meme coin integrations like $UPDOG and $CAW, with some community members expressing bullish sentiment and anticipating a price surge. Additionally, there's excitement surrounding upcoming ASR rewards and a token burn event, driving increased attention and speculation. Despite some concerns about price performance relative to $SOL.X, many see long-term potential in Jupiter's role within the Solana DeFi space.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics (CAPR) is trending as investors await news from the FDA following a Type A meeting, with the community eager for updates on the potential path forward for their Duchenne muscular dystrophy (DMD) treatment, Deramiocel. Community members are closely watching for any signals regarding accelerated approval and expressing frustration with the FDA's handling of the process. Many express support for CAPR's science and leadership and are advocating for a rapid approval.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as investors discuss its upcoming merger with Infleqtion, a quantum computing company. Community interest is rising due to Infleqtion's existing contracts and revenue, with some viewing $CCCX as an undervalued play compared to other quantum stocks like $IONQ and $RGTI. Talk surrounds the potential for significant growth in the quantum computing sector.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo ($OKLO) is trending due to its parabolic run, driven by hype around nuclear energy's potential role in powering AI data centers, though some community members express concerns about its high valuation relative to its lack of current revenue. Discussions also include speculation around upcoming offerings and insider selling, as well as potential catalysts from government support and regulatory developments.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amidst mixed sentiment, with some traders anticipating a drop while others express frustration with its price action and call out perceived "suckers." Discussions also include the potential impact of upcoming Fed rate cuts on altcoins and recent news around Uranium Token xU3O8 debuts on Tezos.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ARQT you are correct no brainer approval coming and buy up any drop you can in the lower 16.00 range as earn coming on November 5 to push us to 20 for sure as recent approvals just peaking in sales and prospects are good for more approvals. Earnings easy for 300 million plus but hoping for 330 million.

Karl Hoffman

Artster25

$ARQT Arcutis (ARQT) is a commercial-stage story with its next catalyst being a low-risk PDUFA on October 13, 2025, aimed at expanding its flagship drug, ZORYVE, to younger children. The core investment thesis, however, is ZORYVE&#39;s &quot;best-in-class&quot; profile: a highly effective, non-steroidal topical that solves the chronic safety issues associated with traditional steroids. This superior profile allows Arcutis to target the massive mild-to-moderate patient population that is underserved by current options. The true measure of success will be in their quarterly sales reports, which will prove their ability to penetrate a competitive market. The upcoming PDUFA is an important incremental step, but the overall bet on ARQT is a belief in strong commercial execution and the market&#39;s inevitable shift towards a safer, more effective standard of care.

StockTwits Web

Arcutis Biotherapeutics Inc

Arkadi

StockTwits for iOS

 you are correct no brainer approval coming and buy up any drop you can in the lower 16.00 range as earn coming on November 5 to push us to 20 for sure as recent approvals just peaking in sales and prospects are good for more approvals. Earnings easy for 300 million plus but hoping for 330 million.

Kurt J Wendler

@Bornjever @Drashkawisha 300million? id be happy with 120. arent you talking for the year?

StockTwits For Android 

 300million? id be happy with 120. arent you talking for the year?